KEFTAB
LOE ApproachingNDAORALTABLET
Approved
Oct 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEFTAB is an oral tablet small-molecule antibiotic approved in 1987 by Eli Lilly and Company. The generic name and specific mechanism of action are not currently available in this dataset. This product represents a mature, legacy antibiotic in the oral tablet format.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team is likely focused on cost management and transition planning rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KEFTAB currently has zero linked job openings, reflecting its mature lifecycle and low commercial activity. Roles supporting this product are primarily defensive and focused on cost management, customer retention, and transition planning rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on KEFTAB at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.